March 02, 2015 11:30 AM ET

Biotechnology

Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for t...

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

Phone:

609-495-2200

Fax:

609-495-2201

Key Executives for Palatin Technologies Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $450.0K
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Age: 57
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

Palatin Technologies Inc. Key Developments

Palatin Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014

Palatin Technologies Inc. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported contract revenue of $8,019,415. Income from operations was $2,322,638 against loss of $3,610,438 a year ago. Income before income taxes was $2,245,280 against loss of $3,606,461 a year ago. Net income was $2,776,788 or $0.03 per diluted share against loss of $3,606,461 or $0.03 per diluted share a year ago. The increase in net income for the quarter ended December 31, 2014 compared to the same period last fiscal year was mainly attributable to the recognition of approximately $8.0 million in contract revenue pursuant to its agreement with Gedeon Richter. For the six months period, the company reported contract revenue of $12,951,730. Income from operations was $3,216,526 against loss of $8,103,088 a year ago. Income before income taxes was $3,039,954 against loss of $8,095,643 a year ago. Net income was $3,571,462 or $0.03 per diluted share against loss of $8,095,643 or $0.08 per diluted share a year ago.

Palatin Technologies Inc. to Report Q2, 2015 Results on Feb 13, 2015

Palatin Technologies Inc. announced that they will report Q2, 2015 results at 11:00 AM, US Eastern Standard Time on Feb 13, 2015

Palatin Technologies Inc., Q2 2015 Earnings Call, Feb 13, 2015

Palatin Technologies Inc., Q2 2015 Earnings Call, Feb 13, 2015

Similar Private Companies By Industry

Company Name Region
Harkness Pharmaceuticals, Inc. United States
Novartis Animal Vaccines, Inc United States
Intravascular Medical United States
Renaissance Biomedical Technologies, Inc. United States
Bridge to Life, Ltd. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 24, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Palatin Technologies Inc., please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.